RYR1: Ryanodine receptor 1
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules.
- Drugs that act on it: 1
- With a US drug page: 1
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Drug | US approval | Mechanism | Action | Warnings |
|---|---|---|---|---|
| Dantrolene | Approved | Ryanodine receptor 1 antagonist | Antagonist | Boxed warning |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Central core myopathy
- 0.85
- Congenital multicore myopathy with external ophthalmoplegia
- 0.84
- King-Denborough syndrome
- 0.80
- Malignant hyperthermia of anesthesia
- 0.80
- RYR1-related myopathy
- 0.70
- Classic multiminicore myopathy
- 0.59
- Ryr1-related disorders
- 0.58
- Myopathy
- 0.57
- Congenital fiber-type disproportion myopathy
- 0.57
- Neuromuscular disease, congenital, with uniform type 1 fiber
- 0.57
- Centronuclear myopathy
- 0.55
- Hereditary disease
- 0.55
Drugs and mechanisms are from ChEMBL CHEMBL1846 (CC BY-SA 3.0). Gene name, function (UniProt P21817, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets